BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21882598)

  • 1. [Molecular markers of lymphatic and blood vessels, tumorigenesis and targets for blocking metastatic spreading].
    Konenkov VI; Borodin IuI; Bgatova NP
    Vopr Onkol; 2011; 57(3):295-301. PubMed ID: 21882598
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular control of lymphatic metastasis.
    Achen MG; Stacker SA
    Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphatic versus blood vascular endothelial growth factors and receptors in humans.
    Partanen TA; Paavonen K
    Microsc Res Tech; 2001 Oct; 55(2):108-21. PubMed ID: 11596156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma.
    Wobser M; Siedel C; Schrama D; Bröcker EB; Becker JC; Vetter-Kauczok CS
    Arch Dermatol Res; 2006 Feb; 297(8):352-7. PubMed ID: 16395613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
    Rafii S; Lyden D; Benezra R; Hattori K; Heissig B
    Nat Rev Cancer; 2002 Nov; 2(11):826-35. PubMed ID: 12415253
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular heterogeneity of tumor endothelium.
    Aird WC
    Cell Tissue Res; 2009 Jan; 335(1):271-81. PubMed ID: 18726119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy.
    Stacker SA; Achen MG
    Lymphat Res Biol; 2008; 6(3-4):165-72. PubMed ID: 19093789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular abnormalities of blood vessels as targets in cancer.
    Baluk P; Hashizume H; McDonald DM
    Curr Opin Genet Dev; 2005 Feb; 15(1):102-11. PubMed ID: 15661540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
    Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
    Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taking down tumors: vascular disrupting agents entering clinical trials.
    O'Hanlon LH
    J Natl Cancer Inst; 2005 Sep; 97(17):1244-5. PubMed ID: 16145041
    [No Abstract]   [Full Text] [Related]  

  • 12. Optical imaging and tumor angiogenesis.
    Lin PC
    J Cell Biochem; 2003 Oct; 90(3):484-91. PubMed ID: 14523982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular-target drug].
    Sone S; Yano S; Nishioka Y
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1034-40. PubMed ID: 15272581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
    Laakkonen P; Waltari M; Holopainen T; Takahashi T; Pytowski B; Steiner P; Hicklin D; Persaud K; Tonra JR; Witte L; Alitalo K
    Cancer Res; 2007 Jan; 67(2):593-9. PubMed ID: 17234768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [VEGF, anti-vEGF and diseases].
    Corvol P
    Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphangiogenesis, inflammation and metastasis.
    Schoppmann SF
    Anticancer Res; 2005; 25(6C):4503-11. PubMed ID: 16334134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor angiogenesis and therapy.
    Cao Y
    Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S340-3. PubMed ID: 16507405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphatic vessel activation in cancer.
    Das S; Skobe M
    Ann N Y Acad Sci; 2008; 1131():235-41. PubMed ID: 18519976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of vascular endothelial growth factor-C and its receptor in invasive micropapillary carcinoma of the breast.
    Li YS; Kaneko M; Amatya VJ; Takeshima Y; Arihiro K; Inai K
    Pathol Int; 2006 May; 56(5):256-61. PubMed ID: 16669874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors.
    Petrova TV; Bono P; Holnthoner W; Chesnes J; Pytowski B; Sihto H; Laakkonen P; Heikkilä P; Joensuu H; Alitalo K
    Cancer Cell; 2008 Jun; 13(6):554-6. PubMed ID: 18538738
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.